Review: Non-alcoholic fatty liver disease in childhood

Abstract

Non-alcoholic fatty liver disease (NAFLD) is an often undiagnosed entity of chronic liver disease with an uncertain prognosis. Recently NAFLD has probably become the most frequent cause of chronic liver disease in children. The term NAFLD covers a spectrum of non-alcoholic fatty liver disease from benign static disease to more aggressive forms that can progress to cirrhosis within childhood. The term non-alcoholic steatohepatitis (NASH) is nowadays reserved to describe these progressive forms of NAFLD. Insulin resistance is a significant aetiological factor and hence a majority of patients with diabetes, obesity and the metabolic syndrome have the disease. Histological confirmation of NAFLD requires 5% steatosis to support the diagnosis and distinguishes an adult (NASH type 1) and a paediatric form (NASH type 2). Current treatment options focus on lifestyle changes to improve underlying obesity and glucose intolerance. This article provides an overview of currently existing data regarding diagnosis and management of children with suspected NAFLD.

Keywords

non-alcoholic fatty liver disease insulin resistance obesity children and adolescents liver biopsy.

Get full access to this article

View all access options for this article.

References

RollestonHD. Diseases of the liver, the gall bladder and the bile ducts. London : MacMillan and Co Limited; 1912 .

Schwimmer JB , Deutsch R. , Kahen T. et al. Prevalence of fatty liver in children and adolescents. Pediatrics 2006;118:1388-93.

Adams LA , Lymp JF , St Sauver J. et al. The natural history of nonalcoholic Fatty liver disease: a population-based cohort study. Gastroenterology 2005;129:113-21.

Angulo P. , Keach JC , Batts KP et al. Independent predictors of liver fibrosis in patients with nonalcoholic steatohepatitis. Hepatology 1999;30:1356-62

Festi D. , Colecchia A. , Sacco T. et al. Hepatic steatosis in obese patients: clinical aspects and prognostic significance. Obes Rev 2004;5:27-42.

Hubscher SG Role of liver biopsy in the assessment of non-alcoholic fatty liver disease . Eur J Gastroenterol Hepatol 2004 ;16:1107-15.

Schwimmer JB , Deutsch R. , Rauch JB et al. Obesity, insulin resistance, and other clinicopathological correlates of pediatric nonalcoholic fatty liver disease . J Pediatr 2003;143:500-05.

Fishbein MH , Miner M. , Mogren C. et al. The spectrum of fatty liver in obese children and the relationship of serum aminotransferases to severity of steatosis. J Pediatr Gastroenterol Nutr 2003;36:54-61.

Vajro P. , Franzese A. , Valerio G. et al. Lack of efficacy of ursodeoxycholic acid for the treatment of liver abnormalities in obese children. J Pediatr 2000;136:739-43.

10.

Lavine JE Vitamin treatment of nonalcoholic steatohepatitis in children: a pilot study . J Peditr 2000;136:734-8.

11.

Lavine JE , Schwimmer JB Pediatric initiatives within the Nonalcoholic Steatohepatitis-Clinical Research Network (NASH CNR). J Pediatr Gastroenterol Nutr 2003;37:220-21.

12.

Lavine JE , Schwimmer JB Nonalcoholic fatty liver disease in the pediatric population. Clin Liver Dis 2004;8:549-58, viii-ix.

13.

Chan DF , Li AM , Chu WC et al. Hepatic steatosis in obese Chinese children. Int J Obes Relat Metab Disord 2004;28:1257-63.

14.

Strauss RS , Barlow SE , Dietz WH Prevalence of abnormal serum aminotransferase values in overweight and obese adolescents. J Pediatr 2000;136:727-33.

15.

Vajro P. , Fontanella A. , Perna C. et al. Persistent hyperaminotransferasemia resolving after weight reduction in obese children. J Pediatr 1994;125:239-41.

16.

Kinugasa A. , Tsunamoto K. , Furukawa N. et al. Fatty liver and its fibrous changes found in simple obesity of children. J Pediatr Gastroenterol Nutr 1984;3:408-14.

17.

Tazawa Y. , Noguchi H. , Nishinomiya F. et al. Serum alanine aminotransferase activity in obese children. Acta Paediatr 1997;86:238-41.

18.

Angulo P. Nonalcoholic fatty liver disease. N Engl J Med 2002;346:1221-31.

19.

Matsusue K. , Haluzik M. , Lambert G. et al. Liver-specific disruption of PPARgamma in leptin-deficient mice improves fatty liver but aggravates diabetic phenotypes . J Clin Invest 2003;111:737-47.

20.

Lin TJ , Lin CL , Wang CS et al. Prevalence of HFE mutations and relation to serum iron status in patients with chronic hepatitis C and patients with nonalcoholic fatty liver disease in Taiwan. World J Gastroenterol 2005 ; 11:3905-08.

21.

Sanyal AJ , Contos MJ , Sterling RK et al. Nonalcoholic fatty liver disease in patients with hepatitis C is associated with features of the metabolic syndrome. Am J Gastroenterol 2003;98:2064-71.

22.

Adams LA , Sanderson S. , Lindor KD et al. The histological course of nonalcoholic fatty liver disease: a longitudinal study of 103 patients with sequential liver biopsies. J Hepatol 2005;42:132-8.

23.

Sasaki A. , Horiuchi N. , Hasegawa K. et al. Mortality and causes of death in type 2 diabetic patients. A long-term follow-up study in Osaka District, Japan. Diabetes Res Clin Pract 1989;7:33-40.

24.

Neuschwander-Tetri BA , Caldwell SH : Nonalcoholic steatohepatitis: summary of an AASLD Single Topic Conference. Hepatology 2003;37:1202-19.

25.

Rashid M. , Roberts EA Nonalcoholic steatohepatitis in children. J Pediatr Gastroenterol Nutr 2000;30:48-53.

26.

Schwimmer JB , Behling C. , Newbury R. et al. Histopathology of pediatric nonalcoholic fatty liver disease . Hepatology 2005;42:641-9.

27.

Baumann U.

Fatty liver disease in childhood - a critical appraisal and results of a survey amongst paediatric gastroenterologists

Dtsch Arztebl 2005;102:A 2634-9.

28.

Baumann U. , McKiernan PJ , Kelly DA The trouble with biopsies. J Pediatr Gastroenterol Nutr 2006;43:122.

29.

Angulo P. , Lindor KD Treatment of nonalcoholic fatty liver: present and emerging therapies . Semin Liver Dis 2001;21:81-8.

30.

Okita M. , Hayashi M. , Sasagawa T. et al. Effect of a moderately energy-restricted diet on obese patients with fatty liver. Nutrition 2001;17:542-7.

31.

Roberts EA , Yap J. Nonalcoholic Fatty Liver Disease (NAFLD): Approach in the Adolescent Patient . Curr Treat Options Gastroenterol 2006;9:423-31.

32.

Dixon JB , Bhathal PS , Hughes NR et al. Nonalcoholic fatty liver disease: Improvement in liver histological analysis with weight loss. Hepatology 2004 ;39:1647-54.

33.

Weiss R. , Dziura J. , Burgert TS et al. Obesity and the metabolic syndrome in children and adolescents . N Engl J Med 2004;350:2362-74.

34.

Vajro P. , Mandato C. , Franzese A. et al. Vitamin E treatment in pediatric obesity-related liver disease: a randomized study. J Pediatr Gastroenterol Nutr 2004;38:48-55.

35.

Bugianesi E. , Gentilcore E. , Manini R. et al. A randomised controlled trial of metformin versus vitamin E on prescriptive diet in non alcoholic fatty liver disease . Am J Gastroenterol 2005;100:1082-90.

36.

Schwimmer JB , Middleton MS , Deutsch R. , Lavine JE A phase 2 clinical trial of metformin as a treatment for non-diabetic paediatric non-alcoholic steatohepatitis. Aliment Pharmacol Ther 2005 ;21:871-9.

37.

Uygun A. , Kadayifci A. , Isik AT et al. Metformin in the treatment of patients with non-alcoholic steatohepatitis . Aliment Pharmacol Ther 2004;19:537-44.

38.

Lavine JE , Schwimmer JB Clinical Research Network launches TONIC trial for treatment of nonalcoholic fatty liver disease in children. J Pediatr Gastroenterol Nutr 2006;42:129-30.

39.

Baldridge AD , Perez-Atayde AR , Graeme-Cook F. et al. Idiopathic steatohepatitis in childhood: a multicenter retrospective study. J Pediatr 1995; 127:700-04.

40.

Brown R. , Dell'Olio D. , Evans H. et al. Isolated portal fibrosis and periportal steatosis are features of paediatric NAFLD. Pediatric and Developmental Pathology 2005;392-23.

41.

Nobili V. , Marcellini M. , Devito R. et al. NAFLD in children: a prospective clinical-pathological study and effect of lifestyle advice. Hepatology 2006;44:458-65.